Solid Biosciences announces Phase 1b trial for SGT-501, a gene therapy for catecholaminergic polymorphic ventricular tachycardia, with FDA designations.
Quiver AI Summary
Solid Biosciences Inc. has announced the approval of its Investigational New Drug application from the FDA for SGT-501, a novel gene therapy targeting catecholaminergic polymorphic ventricular tachycardia (CPVT), a serious genetic heart condition with no existing approved treatments. The therapy has received both Orphan Drug Designation and Rare Pediatric Disease Designation from the FDA and aims to address an urgent medical need. Solid plans to begin a Phase 1b clinical trial for SGT-501 in the fourth quarter of 2025 to assess its safety, tolerability, and efficacy. This innovative gene therapy delivers a functional copy of the CASQ2 gene to heart muscle cells, aiming to correct the underlying calcium dysregulation in CPVT. The development of SGT-501 follows collaborative research led by Dr. Silvia Priori, highlighting the potential of this therapy to transform treatment for patients suffering from this debilitating condition.
Potential Positives
- SGT-501 is a novel gene therapy targeting a rare, life-threatening genetic disease (CPVT) that currently has no approved treatments, highlighting the company's innovative approach to addressing urgent medical needs.
- Solid Biosciences has received both Orphan Drug Designation and Rare Pediatric Disease Designation from the FDA for SGT-501, which could facilitate a faster regulatory process and potential market exclusivity.
- The initiation of a Phase 1b clinical trial for SGT-501 is expected in the fourth quarter of 2025, marking a significant step forward in the company's clinical development pipeline.
- This development expands Solid’s clinical pipeline to include its first cardiac indication, strategically positioning the company in the cardiac therapy market with an innovative genetic treatment approach.
Potential Negatives
- The initiation of the Phase 1b clinical trial for SGT-501 is not expected until the fourth quarter of 2025, indicating a long wait before any potential therapeutic benefit can be assessed for patients suffering from CPVT.
- The company faces significant risks and uncertainties related to advancing SGT-501 and other product candidates on their expected timelines, as well as obtaining necessary regulatory approvals, which could delay or hinder the development process.
- There is a lack of established therapies for CPVT, which may reflect the inherent challenges and complexities associated with developing a successful treatment for this rare condition, creating additional pressure on the company to deliver positive results.
FAQ
What is SGT-501?
SGT-501 is a novel gene therapy for catecholaminergic polymorphic ventricular tachycardia (CPVT), a life-threatening genetic heart condition.
What designations has SGT-501 received from the FDA?
SGT-501 has received Orphan Drug Designation and Rare Pediatric Disease Designation from the FDA.
When does Solid expect to start clinical trials for SGT-501?
Solid expects to initiate a Phase 1b clinical trial of SGT-501 in the fourth quarter of 2025.
What is the unmet need addressed by SGT-501?
SGT-501 targets an urgent unmet medical need for effective treatments for CPVT, which currently has no approved therapies.
Who developed the gene therapy approach used in SGT-501?
The AAV-CASQ2 gene therapy approach utilized by SGT-501 was pioneered by Dr. Silvia Priori and her lab in Italy.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$SLDB Insider Trading Activity
$SLDB insiders have traded $SLDB stock on the open market 12 times in the past 6 months. Of those trades, 3 have been purchases and 9 have been sales.
Here’s a breakdown of recent trading of $SLDB stock by insiders over the last 6 months:
- ADVISORS LLC PERCEPTIVE purchased 5,000,000 shares for an estimated $20,150,000
- CAPITAL LIFE SCIENCES INVESTORS, LLC BAIN purchased 1,000,000 shares for an estimated $4,030,000
- ALEXANDER CUMBO (President and CEO) sold 11,365 shares for an estimated $45,005
- KEVIN TAN (CFO & Treasurer) has made 0 purchases and 2 sales selling 7,237 shares for an estimated $28,378.
- DAVID T HOWTON (Chief Operating Officer) sold 5,561 shares for an estimated $22,021
- GABRIEL BROOKS (Chief Medical Officer) sold 3,256 shares for an estimated $12,893
- JESSIE HANRAHAN (Chief Regulatory Officer) sold 3,079 shares for an estimated $12,192
- PAUL HERZICH (Chief Technology Officer) sold 2,688 shares for an estimated $10,644
- CLARE KAHN purchased 1,860 shares for an estimated $9,924
- ILAN GANOT has made 0 purchases and 2 sales selling 1,855 shares for an estimated $7,223.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$SLDB Hedge Fund Activity
We have seen 90 institutional investors add shares of $SLDB stock to their portfolio, and 31 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- COMMODORE CAPITAL LP added 5,825,000 shares (+inf%) to their portfolio in Q1 2025, for an estimated $21,552,500
- PERCEPTIVE ADVISORS LLC added 5,000,000 shares (+72.4%) to their portfolio in Q1 2025, for an estimated $18,500,000
- ADAGE CAPITAL PARTNERS GP, L.L.C. added 4,981,400 shares (+285.0%) to their portfolio in Q1 2025, for an estimated $18,431,180
- BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC added 3,877,087 shares (+96.1%) to their portfolio in Q1 2025, for an estimated $14,345,221
- SIREN, L.L.C. added 3,666,864 shares (+97.8%) to their portfolio in Q1 2025, for an estimated $13,567,396
- FMR LLC added 3,471,183 shares (+7432.1%) to their portfolio in Q1 2025, for an estimated $12,843,377
- VR ADVISER, LLC added 2,481,400 shares (+inf%) to their portfolio in Q1 2025, for an estimated $9,181,180
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$SLDB Analyst Ratings
Wall Street analysts have issued reports on $SLDB in the last several months. We have seen 10 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Citigroup issued a "Buy" rating on 06/26/2025
- HC Wainwright & Co. issued a "Buy" rating on 06/17/2025
- JMP Securities issued a "Market Outperform" rating on 06/06/2025
- Cantor Fitzgerald issued a "Overweight" rating on 05/22/2025
- Chardan Capital issued a "Buy" rating on 05/19/2025
- Piper Sandler issued a "Overweight" rating on 05/16/2025
- Wedbush issued a "Outperform" rating on 05/16/2025
To track analyst ratings and price targets for $SLDB, check out Quiver Quantitative's $SLDB forecast page.
$SLDB Price Targets
Multiple analysts have issued price targets for $SLDB recently. We have seen 10 analysts offer price targets for $SLDB in the last 6 months, with a median target of $15.0.
Here are some recent targets:
- Yigal Nochomovitz from Citigroup set a target price of $14.0 on 06/26/2025
- Arthur He from HC Wainwright & Co. set a target price of $20.0 on 06/17/2025
- Silvan Tuerkcan from JMP Securities set a target price of $15.0 on 06/06/2025
- Kristen Kluska from Cantor Fitzgerald set a target price of $16.0 on 05/22/2025
- Geulah Livshits from Chardan Capital set a target price of $15.0 on 05/19/2025
- Biren Amin from Piper Sandler set a target price of $17.0 on 05/16/2025
- Laura Chico from Wedbush set a target price of $17.0 on 05/16/2025
Full Release
- SGT-501 is a novel gene therapy for rare, life-threatening, genetic arrhythmogenic disease with no approved therapies -
- SGT-501 has received Orphan Drug Designation and Rare Pediatric Disease Designation from the FDA -
- Solid expects to initiate Phase 1b clinical trial of SGT-501 in the fourth quarter of 2025 -
- Expands Solid’s clinical pipeline to include first cardiac indication with urgent unmet medical need -
CHARLESTOWN, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced approval of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) and clinical trial application (CTA) by Health Canada for SGT-501, a novel gene therapy approach for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT), a highly malignant, arrhythmogenic channelopathy caused by genetic mutations that impact the ryanodine receptor (RYR2) in cardiac muscle. The Company expects to initiate a Phase 1b clinical trial to evaluate the safety, tolerability and efficacy of SGT-501 in the fourth quarter of 2025.
Gabriel Brooks, M.D., Chief Medical Officer of Solid, said: “Despite being identified nearly 50 years ago, CPVT still lacks FDA-approved therapies – this announcement reflects a critical development in the treatment of this underserved, often fatal, cardiac disease. SGT-501 offers a precision genetic approach targeting the underlying pathophysiology of the disease: abnormal calcium releases from the sarcoplasmic reticulum in an otherwise structurally sound heart. We believe SGT-501 has the unique potential to provide durable protection and may be capable of liberating patients from the ever-present threat of lethal arrhythmias and life-limiting prohibitions on exercise. Solid is proud to launch this program to help address this clear unmet need, further expanding our pipeline of differentiated and thoughtfully designed genetic medicines.”
Silvia Priori, M.D., Ph.D., Professor of Cardiology at the University of Pavia and Director of the Molecular Cardiology Unit at the IRCCS Maugeri in Pavia, Italy, said: “After decades during which we, the clinical community, have been limited in our ability to treat people living with CPVT, I have long hoped for the day when a genetic-modifying therapy becomes available. We are proud to partner with Solid who advanced fundamental work from our labs at Maugeri, which demonstrated the principle that calsequestrin overexpression can have a therapeutic impact on multiple forms of CPVT in both cellular and mouse models of disease. This work was further developed into a compelling IND safety and efficacy package through close collaboration with, and studies conducted by, the Solid team. I look forward to clinical updates for SGT-501 and seeing how this potential medicine may benefit people living with CPVT who are in critical need of disease-specific medicines.”
About SGT-501
SGT-501 is an AAV-based gene therapy candidate designed to deliver a functional, full length, codon-optimized copy of the human cardiac calsequestrin (CASQ2) gene to heart muscle cells. In the context of RYR2 variants, increasing CASQ2 protein levels enhances buffering of free calcium in the sarcoplasmic reticulum, stabilizing the RYR2, which results in reduced diastolic calcium leak into the cytosol. Stabilization of the RYR2 in its closed conformation supports the maintenance of normal cardiac rhythm with the potential to protect against ventricular tachycardia. SGT-501 received Orphan Drug Designation and Rare Pediatric Disease Designation from the U.S. FDA and has potential as a first-in-class therapy to correct the underlying RYR2 instability and calcium dysregulation causes of CPVT.
The AAV-CASQ2 gene therapy approach utilized by SGT-501 was pioneered by Dr. Silvia Priori and the IRCCS ICS Maugeri lab in Pavia, Italy. As a globally recognized leader in inherited arrhythmias, Dr. Priori has long been at the forefront of translational cardiac research. Solid Biosciences in-licensed this innovative therapeutic in 2023 and subsequently advanced it into IND-enabling preclinical development, marking an important step toward bringing this potential treatment to individuals living with CPVT.
About Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a heart condition marked by abnormal rhythms; specifically, an abnormally fast heartbeat (ventricular tachycardia), which can be triggered by adrenergic stimulation such as physical activity or emotional stress. These arrhythmias can cause unexplained fainting, seizures, cardiac arrest and sudden death. CPVT is estimated to affect roughly 1 in 10,000 individuals globally, although it is often misdiagnosed, and is typically identified in children and young adults. It is mainly caused by mutations in the RYR2 and CASQ2 genes, which disrupt calcium regulation in heart muscle cells, impairing proper heart contraction and relaxation. There are currently no treatments that address the underlying mechanisms of CPVT.
To learn more about CPVT and SGT-501, watch a brief CPVT expert and patient video by clicking here.
About Istituti Clinici Scientifici Maugeri Spa SB (ICS Maugeri)
ICS Maugeri S.p.A. Società Benefit is Italy’s leading healthcare provider specializing in rehabilitation and comprehensive care for vulnerable patients. It stands out for its strong focus on scientific research, operating 18 Clinical Institutes - including 9 recognized as IRCCS (Scientific Institutes for Research, Hospitalization and Healthcare) and 9 as Scientific Clinical Institutes -along with 6 outpatient centers, 1 Environmental Research Center, and a Poison Control Center and National Toxicology Information Center.
ICS Maugeri is involved not only in scientific research but also in the application of advanced technologies across medical disciplines, offering personalized care pathways and centers of excellence for specific conditions and clinical specialties. The Group employs more than 4,000 professionals, where medical and professional excellence is intrinsically linked to core values of equity, inclusivity, equality, and transparency - principles that have always guided Maugeri’s mission.
Headquartered in Pavia, ICS Maugeri operates 23 healthcare facilities across 7 Italian regions, including 9 IRCCS, 10 Scientific Clinical Institutes, 5 outpatient clinics, a Poison Control Center –Toxicology Center, and an Environmental Research Center.
About Solid Biosciences
Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, including Duchenne muscular dystrophy (Duchenne), Friedreich’s ataxia (FA), catecholaminergic polymorphic ventricular tachycardia (CPVT), TNNT2-mediated dilated cardiomyopathy, BAG3-mediated dilated cardiomyopathy, and additional fatal, genetic cardiac diseases. The Company is also focused on developing innovative libraries of genetic regulators and other enabling technologies with promising potential to significantly impact gene therapy delivery cross-industry. Solid is advancing its diverse pipeline and delivery platform in the pursuit of uniting experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted by Duchenne, Solid’s mission is to improve the daily lives of patients living with devastating rare diseases. For more information, please visit
www.solidbio.com
.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding future expectations, plans and prospects for the Company; the ability to successfully achieve and execute on the company’s goals, priorities and achieve key clinical milestones; the Company’s pipeline of programs for neuromuscular and cardiac diseases, including its SGT-501, SGT-212 and SGT-003 programs and expectations for CTA filings, site activations, clinical development, initiation and enrollment in clinical trials, dosing, availability of clinical trial data and potential accelerated approval; the sufficiency of the Company’s cash, cash equivalents, and available-for-sale securities to fund its operations; and other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” “working” and similar expressions. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. These risks and uncertainties include, but are not limited to, risks associated with the company’s ability to advance SGT-501, SGT-212, SGT-003, SGT-601, SGT-401 and other preclinical programs and capsid libraries on the timelines expected or at all; obtain and maintain necessary approvals from the FDA and other regulatory authorities; replicate in clinical trials positive results found in preclinical studies and early-stage clinical trials of the company’s product candidates; obtain, maintain or protect intellectual property rights related to its product candidates; compete successfully with other companies that are seeking to develop Duchenne, Friedreich’s ataxia and other neuromuscular and cardiac treatments and gene therapies; manage expenses; and raise the substantial additional capital needed, on the timeline necessary, to continue development of SGT-501, SGT-212, SGT-003, SGT-601, SGT-401 and other candidates, achieve its other business objectives and continue as a going concern. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the company’s actual results to differ from those contained in the forward-looking statements, see the “Risk Factors” section, as well as discussions of potential risks, uncertainties and other important factors, in the company’s most recent filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the company’s views as of the date hereof and should not be relied upon as representing the company’s views as of any date subsequent to the date hereof. The company anticipates that subsequent events and developments will cause the company's views to change. However, while the company may elect to update these forward-looking statements at some point in the future, the company specifically disclaims any obligation to do so.
Solid Biosciences Investor Contact:
Nicole Anderson
Director, Investor Relations and Corporate Communications
Solid Biosciences Inc.
[email protected]
Media Contact:
Yuliya Kutuzava
FINN Partners
[email protected]